About Nucleobindin-1
Nucleobindin-1 (NUCB1) is a protein
from Homo sapiens identified by UniProt accession
Q02818, 461 residues long.
MolForge cross-references it against 0 known binders and
110 disease associations.
Target properties
| Protein name | Nucleobindin-1 |
|---|
| UniProt accession | Q02818 |
|---|
| Gene | NUCB1 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 461 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (110)
Diseases linked to this target (Open Targets).
- visual perception measurement · score 0.18
- diffuse large B-cell lymphoma · score 0.07
- breast cancer · score 0.07
- neoplasm · score 0.06
- mean corpuscular volume · score 0.04
- hepatorenocardiac degenerative fibrosis · score 0.04
- mean corpuscular hemoglobin concentration · score 0.04
- Senior-Boichis syndrome · score 0.03
- cancer · score 0.03
- Beta-thalassemia · score 0.03
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q02818-F1 | alphafold | PREDICTED | 78.78 | — |
Amino-acid sequence (461 residues)
MPPSGPRGTL LLLPLLLLLL LRAVLAVPLE RGAPNKEETP ATESPDTGLY YHRYLQEVID VLETDGHFRE KLQAANAEDI KSGKLSRELD FVSHHVRTKL DELKRQEVSR LRMLLKAKMD AEQDPNVQVD HLNLLKQFEH LDPQNQHTFE ARDLELLIQT ATRDLAQYDA AHHEEFKRYE MLKEHERRRY LESLGEEQRK EAERKLEEQQ RRHREHPKVN VPGSQAQLKE VWEELDGLDP NRFNPKTFFI LHDINSDGVL DEQELEALFT KELEKVYDPK NEEDDMREME EERLRMREHV MKNVDTNQDR LVTLEEFLAS TQRKEFGDTG EGWETVEMHP AYTEEELRRF EEELAAREAE LNAKAQRLSQ ETEALGRSQG RLEAQKRELQ QAVLHMEQRK QQQQQQQGHK APAAHPEGQL KFHPDTDDVP VPAPAGDQKE VDTSEKKLLE RLPEVEVPQH L
Explore Nucleobindin-1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets